St. John's Wort
Traditional medicine (herbal / TCM) targets CYP2C19, CYP3A4 via activation
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01726764 | Jan → Jun 2013 | depressive disorder, type 2 diabetes mellitus | University of Southern Denmark | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT00451516 | Mar → Oct 2007 | anxiety disorder, major depressive disorder | The University of Queensland | Completed | No outcome recorded |
| Phase 2 | NCT00110136 | Mar 2006 → Apr 2008 | breast cancer | Wake Forest University Health Sciences | Terminated | Missed primary |
| Phase 2 | NCT00405912 | Sep 2005 → Mar 2008 | nicotine dependence | Mayo Clinic | Completed | Missed primary |
| Phase 2 | NCT00035438 | May 2002 → Sep 2003 | obsessive-compulsive disorder | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00035412 | Dec 2001 → Aug 2004 | social phobia | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02840331 | Jul 2017 → Dec 2019 | peritoneal carcinomatosis | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 3 | NCT00782080 | Jul 2008 → Mar 2010 | attention deficit-hyperactivity disorder | Prof. Huss | Completed | No outcome recorded |
| Phase 3 | NCT00351117 | Mar 2007 → Aug 2008 | Raynaud disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT01938859 | Jun 2012 → Dec 2017 | bipolar disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT00557427 | Jan 2009 → Nov 2010 | depressive disorder | Rafa Laboratories | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00131885 | Aug 2005 → May 2008 | — | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT00027014 | Sep 2001 → May 2005 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 4 | NCT00006395 | Oct 2000 → Apr 2001 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01330589 | Apr 2011 → Mar 2015 | acute coronary syndrome | Lancaster General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00048815 | Feb 2003 → Apr 2007 | depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00587860 Comparator | Feb 2006 → Jan 2008 | irritable bowel syndrome | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | St. John's wort | “The purpose of this study is to evaluate whether patients post PCI receiving clopidogrel who are carriers of at least one CYP 2C19 loss-of-function allele may achieve improved...” NCT01330589 ↗16“This pilot study examined the effectiveness, safety, tolerability, and pharmacodynamics of Hypericum perforatum (St. John's wort) in the treatment of youths diagnosed with...” PMID 12874492 ↗ Aug 2003 “St. John's Wort (Hypericum perforatum) orally or 4-6 weeks” NCT00131885 ↗ “St. John´s Wort (100 mg) Valerian Extract (50 mg)” NCT00782080 ↗ “Other: St John's Wort” NCT01726764 ↗ |
| Known as | hypericum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00557427 ↗ |
| Known as | Hypericum perforatum | “This pilot study examined the effectiveness, safety, tolerability, and pharmacodynamics of Hypericum perforatum (St. John's wort) in the treatment of youths diagnosed with...” PMID 12874492 ↗ Aug 20034“There has been considerable worldwide interest in St. John's Wort (SJW) (Hypericum perforatum) as a treatment of mild to moderate depression.” NCT00035412 ↗ “Extract of St. John's wort (SJW: Hypericum perforatum) has gained widespread popularity as an over-the-counter, natural antidepressant.” NCT00027014 ↗ “Determine the efficacy of Hypericum perforatum (St. John's wort) in alleviating hot flashes” NCT00110136 ↗ “St. John's Wort (Hypericum perforatum) orally or 4-6 weeks” NCT00131885 ↗ |
| Known as | LI 160 | “Forty patients will be randomized to either SJW (LI 160) or matching placebo.” NCT00035412 ↗ |
| Known as | SGJY, St.John's wort and acanthopanax senticosus combination | “TCM named as Shuganjieyu capsule (SGJY, St. John's wort and acanthopanax senticosus combination).” NCT01938859 ↗ |
| Known as | Shuganjieyu capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01938859 ↗ |
| Known as | SJW | “The objective of the proposed study is to assess the efficacy of the herbal St. John's Wort (SJW) in the treatment of symptoms of obsessive-compulsive disorder (OCD).” NCT00035438 ↗2“There has been considerable worldwide interest in St. John's Wort (SJW) (Hypericum perforatum) as a treatment of mild to moderate depression.” NCT00035412 ↗ “Extract of St. John's wort (SJW: Hypericum perforatum) has gained widespread popularity as an over-the-counter, natural antidepressant.” NCT00027014 ↗ |
| Action | Activate | “SJW treatment may increase the activity of a transporter protein, named P-glycoprotein (Pgp), in the blood-brain barrier (BBB) that protects the brain from exposure to drugs...” NCT00027014 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a common herbal remedy” NCT00131885 ↗ |
| Route | Oral | “taken orally” NCT00048815 ↗ |
| Target | CYP3A4 | “induce previously induced CYP3A4 enzyme activity” NCT00006395 ↗ |